Price alert —
Sign in to get a one-time email the moment BIIB crosses your price. Free accounts included.
Sign in / create a free accountPrice chart
Loading…
Latest bar · BIIB
Momentum reads · latest daily barGreen means room to run, red means stretched — the reads re-read live as you switch the chart's timeframe. MFI(14) is a volume-weighted money-flow read: above 80 = overbought, below 20 = oversold.
Financial overlay · last 12 quarters
The story behind the price: three years of quarterly results laid over the chart, so you can see whether the stock has been following the business — or running ahead of it.
| Quarter | Revenue | Net income | Op income | FCF | Net margin | Op margin |
|---|---|---|---|---|---|---|
| 2026-03-31 | $2.5B | $0.3B | $0.5B | $0.6B | 12.9% | 18.6% |
| 2025-12-31 | $2.3B | $-0.0B | $0.4B | $0.4B | -2.1% | 16.9% |
| 2025-09-30 | $2.5B | $0.5B | $0.6B | $1.2B | 18.4% | 23.9% |
| 2025-06-30 | $2.6B | $0.6B | $0.9B | $0.1B | 24.0% | 32.2% |
| 2025-03-31 | $2.4B | $0.2B | $0.6B | $0.2B | 9.9% | 25.7% |
| 2024-12-31 | $nanB | $nanB | $nanB | $nanB | nan% | nan% |
Tip: toggle P/E, FCF, ROE, Gross margin and more on the chart above — every overlay is free.
Compare BIIB vs peers
Line BIIB up against up to 4 peers (5 tickers total) across ~30 metrics and get one weighted 0-100 verdict — best in green, worst in red. Peers also overlay on the chart above as rebased % lines, or flip the chart to the 2×2 grid for side-by-side mini charts.
Add tickers to compare with BIIB
~30 metrics across Snapshot, OdysseyHQ zone, Valuation, Growth, Quality, Technicals, Sentiment, and Risk — with a weighted score and a one-line read on each.
Earnings replay · last 20 reports
How this stock actually behaves on report day: each past earnings print with the beat-or-miss and the next-day move — a track record for handicapping the next one.
| Date | EPS actual | EPS est | Surprise | Next-day |
|---|---|---|---|---|
| 2026-04-29 | 3.57 | 2.89 | +23.6% | -2.6% |
| 2026-02-06 | 1.99 | 1.62 | +23.2% | -3.7% |
| 2025-10-30 | 4.81 | 3.88 | +23.9% | +3.1% |
| 2025-07-31 | 5.47 | 3.88 | +41.0% | +3.1% |
| 2025-05-01 | 3.02 | 2.95 | +2.4% | +2.1% |
| 2025-02-12 | 3.44 | 3.36 | +2.3% | +3.8% |
| 2024-10-30 | 4.08 | 3.79 | +7.8% | -4.0% |
| 2024-08-01 | 5.28 | 4.03 | +31.0% | -2.4% |
| 2024-04-24 | 3.67 | 3.46 | +6.0% | +0.2% |
| 2024-02-13 | 2.95 | 3.18 | -7.2% | -2.6% |
| 2023-11-08 | 4.36 | 3.98 | +9.4% | -3.0% |
| 2023-07-25 | 4.02 | 3.76 | +6.9% | -1.9% |
| 2023-04-25 | 3.40 | 3.28 | +3.5% | +2.0% |
| 2023-02-15 | 4.05 | 3.48 | +16.2% | -2.7% |
| 2022-10-25 | 4.77 | 4.13 | +15.5% | +2.5% |
| 2022-07-20 | 5.25 | 4.07 | +29.0% | +3.2% |
| 2022-05-03 | 3.62 | 4.36 | -17.0% | +2.1% |
| 2022-02-03 | 3.39 | 3.37 | +0.6% | +0.6% |
| 2021-10-20 | 4.77 | 4.10 | +16.5% | +1.4% |
| 2021-07-22 | 5.68 | 4.60 | +23.5% | — |
Earnings markers are overlaid on the daily price chart above. Click a ▲ marker for that day's move.
Peer comparison · Healthcare
Context check: the same key numbers for the closest Healthcare names side by side, so you can tell whether this stock is the standout or just moving with its group.
| Ticker ⇅ | Mkt cap ⇅ | P/E ⇅ | Fwd P/E ⇅ | P/S ⇅ | EV/EBITDA ⇅ | P/B ⇅ | Gross M ⇅ | Rev gr ⇅ | EPS gr ⇅ | FCF yld ⇅ |
|---|---|---|---|---|---|---|---|---|---|---|
| BIIB ★ | $29B | 21.3 | 12.0 | 2.9 | 9.1 | 1.6 | 78.7% | 1.9% | 31.1% | 6.61% |
| LLY | $1,037B | 41.4 | 25.9 | — | 30.0 | 33.3 | 82.8% | 55.5% | 169.9% | 0.88% |
| UNH | $392B | 32.5 | 19.2 | 0.9 | 18.1 | 3.7 | 19.5% | 0.4% | 61.5% | 5.81% |
| JNJ | $615B | 29.7 | 19.9 | 6.3 | 18.3 | 7.6 | 68.1% | 6.6% | -1.0% | — |
| MRK | $315B | 35.9 | 13.2 | — | 12.0 | 6.9 | 76.7% | 4.9% | — | 4.46% |
| ABBV | $448B | 123.6 | 15.6 | 7.1 | 17.2 | -67.2 | 72.0% | 12.4% | -46.2% | 4.65% |
| PFE | $141B | 18.9 | 8.8 | — | 7.6 | 1.6 | 74.8% | 5.4% | -10.1% | 8.75% |
| TMO | $196B | 29.0 | 19.3 | — | 20.8 | 3.8 | 40.9% | 6.2% | 11.3% | 2.82% |
Auto-seeded from sector. Click any ticker to switch.
Ownership
Who holds the stock and what they've been doing lately — big funds on the left, executives' own buys and sells on the right. Insider buying is the rarer, louder signal.
Top institutional holders
Top-10 concentration: 53.03%
| Holder | Shares | % out |
|---|---|---|
| Blackrock Inc. | 15,974,601 | 10.82% |
| Primecap Management Company | 14,757,607 | 10.00% |
| FMR, LLC | 12,807,541 | 8.68% |
| Vanguard Capital Management LLC | 9,537,417 | 6.46% |
| State Street Corporation | 7,167,922 | 4.86% |
| Vanguard Portfolio Management LLC | 6,531,727 | 4.42% |
| Geode Capital Management, LLC | 4,342,602 | 2.94% |
| Wellington Management Group, LLP | 2,961,641 | 2.01% |
| Morgan Stanley | 2,170,940 | 1.47% |
| JPMORGAN CHASE & CO | 2,016,009 | 1.37% |
Insider activity · 90d
9 buys / 0 sells · ratio 9.0 · Finnhub
- Minor Lloyd BUY 3,875
- Pangalos Menelas N M 0
- Pangalos Menelas N BUY 3,875
- Pangalos Menelas N M 2,370
- LANGER SUSAN BUY 6,634
- Patolawala Monish D BUY 5,215
- Mantas Jesus B BUY 11,263
- Freire Maria C BUY 8,820
- Rowinsky Eric K BUY 25,844
- HAWKINS WILLIAM A BUY 10,365
Analyst estimates
FinnhubWhat Wall Street expects next: the consensus forecasts for the coming quarters. The market usually reacts to results versus these numbers, not the raw results themselves.
SEC filings
The company's own paperwork, straight from the regulator — annual and quarterly reports, big announcements and insider trades. The primary source behind every headline.
| Form | Filed | Description | Action |
|---|---|---|---|
| 8-K | 2026-07-01 | 8-K | view · |
| 4 | 2026-06-11 | PRIMARY DOCUMENT | view · |
| 4 | 2026-06-11 | PRIMARY DOCUMENT | view · |
| 4 | 2026-06-11 | PRIMARY DOCUMENT | view · |
| 4 | 2026-06-11 | PRIMARY DOCUMENT | view · |
| 4 | 2026-06-11 | PRIMARY DOCUMENT | view · |
| 4 | 2026-06-11 | PRIMARY DOCUMENT | view · |
| 4 | 2026-06-11 | PRIMARY DOCUMENT | view · |
| 4 | 2026-06-11 | PRIMARY DOCUMENT | view · |
| 4 | 2026-06-11 | PRIMARY DOCUMENT | view · |
| 8-K | 2026-06-10 | CURRENT REPORT | view · |
| 8-K | 2026-05-14 | 8-K | view · |
| 4 | 2026-05-05 | PRIMARY DOCUMENT | view · |
| 10-Q | 2026-04-29 | 10-Q | view · |
| 8-K | 2026-04-29 | 8-K | view · |
| DEF 14A | 2026-04-28 | DEF 14A | view · |
| 8-K | 2026-04-06 | 8-K | view · |
| 4 | 2026-04-03 | PRIMARY DOCUMENT | view · |
| 8-K | 2026-03-31 | 8-K | view · |
| 8-K | 2026-03-11 | CURRENT REPORT | view · |
| 4 | 2026-02-17 | PRIMARY DOCUMENT | view · |
| 4 | 2026-02-17 | PRIMARY DOCUMENT | view · |
| 4 | 2026-02-17 | PRIMARY DOCUMENT | view · |
| 4 | 2026-02-17 | PRIMARY DOCUMENT | view · |
| 4 | 2026-02-17 | PRIMARY DOCUMENT | view · |
| 4 | 2026-02-17 | PRIMARY DOCUMENT | view · |
| 4 | 2026-02-17 | PRIMARY DOCUMENT | view · |
| 4 | 2026-02-17 | PRIMARY DOCUMENT | view · |
| 4 | 2026-02-17 | PRIMARY DOCUMENT | view · |
| 4 | 2026-02-17 | PRIMARY DOCUMENT | view · |
| 8-K | 2026-02-11 | 8-K | view · |
| 4 | 2026-02-10 | PRIMARY DOCUMENT | view · |
| 4 | 2026-02-10 | PRIMARY DOCUMENT | view · |
| 4 | 2026-02-10 | PRIMARY DOCUMENT | view · |
| 4 | 2026-02-10 | PRIMARY DOCUMENT | view · |
| 4 | 2026-02-10 | PRIMARY DOCUMENT | view · |
| 4 | 2026-02-10 | PRIMARY DOCUMENT | view · |
| 4 | 2026-02-10 | PRIMARY DOCUMENT | view · |
| 4 | 2026-02-10 | PRIMARY DOCUMENT | view · |
| 4 | 2026-02-10 | PRIMARY DOCUMENT | view · |
| 4 | 2026-02-10 | PRIMARY DOCUMENT | view · |
| 10-K | 2026-02-06 | 10-K | view · |
| 8-K | 2026-02-06 | 8-K | view · |
| 4 | 2026-02-03 | PRIMARY DOCUMENT | view · |
| 8-K | 2026-01-14 | 8-K | view · |
| 4 | 2025-12-03 | PRIMARY DOCUMENT | view · |
| 4 | 2025-11-04 | PRIMARY DOCUMENT | view · |
| 10-Q | 2025-10-30 | 10-Q | view · |
| 8-K | 2025-10-30 | 8-K | view · |
| 8-K | 2025-10-14 | 8-K | view · |
| 4 | 2025-10-06 | PRIMARY DOCUMENT | view · |
| 4 | 2025-09-02 | PRIMARY DOCUMENT | view · |
| 8-K | 2025-07-31 | 8-K | view · |
| 10-Q | 2025-07-31 | 10-Q | view · |
| 4 | 2025-07-16 | PRIMARY DOCUMENT | view · |
| 8-K | 2025-07-07 | 8-K | view · |
| 8-K | 2025-06-23 | 8-K | view · |
| 4 | 2025-06-18 | PRIMARY DOCUMENT | view · |
| 4 | 2025-06-18 | PRIMARY DOCUMENT | view · |
| 4 | 2025-06-18 | PRIMARY DOCUMENT | view · |
About BIIB
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE. It offers LEQEMBI for the treatment of Alzheimer's disease; ZURZUVAE for the treatment of postpartum depression; RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for aRelapsed or refractory diffuse large B-cell lymphoma; and other anti-CD20 therapies. Biogen Inc. has collaboration and license a…
Options picks · BIIB
ITM + OTM ideas from the latest scanLoading…
Congress trades · BIIB
STOCK Act disclosuresLoading…
SEC filings & insiders · BIIB
EDGAR · liveLoading…
Holders · BIIB
Institutions & insider activityLoading…